News
STAB
--
0.00%
--
Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell
Statera BioPharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that President and CEO Michael K. Handley and other members of the manag...
PR Newswire · 09/09 17:08
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) —
Benzinga · 09/08 11:55
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.
Benzinga · 09/08 08:57
Statera BioPharma: The Ticker Formerly Known as CBLI
On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets. 
Benzinga · 09/07 12:06
Statera BioPharma Provides Update On Integration Of ImQuest
Statera BioPharma, Inc. Provides Update on Integration of ImQuest FORT COLLINS, Colo., Sept. 1, 2021 /PRNewswire/ -- Statera BioPharma (NASDAQ:STAB), a leading biopharmaceutical company creating
Benzinga · 09/01 13:25
Statera BioPharma, Inc. Provides Update on Integration of ImQuest
/PRNewswire/ --  (NASDAQ: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update on the integration of the ImQuest BioSciences business unit and the st...
PR Newswire - PRF · 09/01 13:20
BRIEF-Cytocom Plans To Adopt New Corporate Name "Statera Biopharma, Inc."
reuters.com · 08/31 11:36
58 Biggest Movers From Friday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
Benzinga · 08/23 09:06
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast
Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of the second quarter 2021 corporate and financial results ...
PR Newswire · 08/16 14:34
BRIEF-Cytocom Inc Reports Q2 Loss Per Share Of $0.04 Excluding Minority Interests
reuters.com · 08/16 11:35
BRIEF-Cytocom Q2 Loss Per Share Of $0.04
reuters.com · 08/16 11:24
Cleveland BioLabs Q2 EPS $(0.04) Down From $(0.03) YoY
Cleveland BioLabs (NASDAQ:CBLI) reported quarterly losses of $(0.04) per share. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year.
Benzinga · 08/16 11:24
Cytocom Enters Research Collaboration Agreement With La Jolla Institute for Immunology
MT Newswires · 08/13 11:59
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement
/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the (L...
PR Newswire - PRF · 08/12 20:05
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Busines...
PR Newswire - PRF · 08/11 11:30
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, ...
PR Newswire - PRF · 08/10 11:30
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
Cytocom Inc.  (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its
Benzinga · 08/09 11:52
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs. ...
PR Newswire - PRF · 08/05 11:33
Webull provides a variety of real-time STAB stock news. You can receive the latest news about Statera BioPharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About STAB
Statera BioPharma, Inc., formerly Cytocom, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies targeting autoimmune, neutropenia/anemia, viruses and cancers. Its Advanced Immunomodulating Multi-component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200, STAT-400 and STAT-600 AIMS programs. Its STAT-200 program includes STAT-201, STAT-205, STAT-203 and STAT-202. STAT-201 is focused the treatment of Crohn’s disease. STAT-205 is focused on treatment of acute and post-acute coronavirus (COVID 19). Its STAT-400 programs include STAT-401 and STAT-400. STAT-401 is an injectable pentapeptide that is targeted for patients with pancreatic cancer.